• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Lengthy remission rates uphold alefacept quality of life benefits

Article

Maui, Hawaii - Alefacept (Amevive) for treating patients with chronic plaque psoriasis provides clinical benefits that may be long-term and are associated with significant improvement in quality of life, Mark Lebwohl, M.D., said at the 26th annual Hawaii Dermatology Seminar.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.